ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

UCSF Spin-Off Scores Venture Financing

by Lisa M. Jarvis
July 12, 2010 | APPEARED IN VOLUME 88, ISSUE 28

Calithera, a spin-off from the University of California, San Francisco, has raised $40 million in its first round of financing. The biotech firm was formed to commercialize caspase activation technology developed in the lab of Jim Wells, chair of the pharmaceutical chemistry department in UCSF’s School of Pharmacy. Wells has found several small molecules that convert caspases from an inactive form into enzymes that destroy cancer cells. Morgenthaler Ventures led the financing round. Mission Bay Capital, U.S. Venture Partners, Advanced Technology Ventures, and Delphi Ventures all participated.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment